COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,043 Articles (22,627 medRxiv, 8,416 bioRxiv)

Most recent first Previous |  Page 1269: Articles 12681-12690  | Next

CORONAVIRUS DISEASE 2019 IN A TERTIARY PEDIATRIC CENTER IN PORTUGAL
Milheiro Silva, T., Garcia, A. M., Gouveia, C., Candeias, F., Brito, M. J.
10.1101/2021.08.16.21262100 — Posted: 2021-08-22
Modeling SARS-CoV-2 transmission at a winter destination resort region with high outside visitation
Wu, E. J., Bayham, J., Carlton, E. J., Samet, J. M., Buchwald, A. G.
10.1101/2021.08.18.21262227 — Posted: 2021-08-22
Studies on the level of neutralizing antibodies produced by inactivated COVID-19 vaccines in the real world
Zhang, H., Jia, Y., Ji, Y., Cong, X., Liu, Y., Yang, R., Kong, X., Shi, Y., Zhu, L., Wang, Z., Wang, W., Fei, R., Liu, F., Lu, F., Chen, H., Rao, H.
10.1101/2021.08.18.21262214 — Posted: 2021-08-22
Dynamics of SARS-CoV-2 exposure in Malawian blood donors: a retrospective seroprevalence analysis between January 2020 and February 2021
Mandolo, J., Msefula, J., Henrion, M. Y., Brown, C., Moyo, B., Samon, A., Moyo-Gwete, T., Makhado, Z., Ayres, F., Motlou, T., Mzindle, N., Kalata, N., Muula, A. S., Kwatra, G., Msamala, N., Likaka, A., Mfune, T., Moore, P. L., Mbaya, B., French, N., Heyderman, R. S., Swarthout, T. D., Jambo, K. C.
10.1101/2021.08.18.21262207 — Posted: 2021-08-22
Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY): Statistical analysis plan for a randomised controlled Bayesian adaptive sample size trial
McGree, J., Hockham, C., Kotwal, S., Wilcox, A., Bassi, A., Pollock, C., Burrell, L. M., Snelling, T., Jha, V., Jardine, M., Jones, M.
10.1101/2021.08.17.21262196 — Posted: 2021-08-22
Interpreting Wastewater SARS-CoV-2 Results using Bayesian Analysis
Curtis, K., Gonzalez, R. A.
10.1101/2021.08.17.21262165 — Posted: 2021-08-22
Assessment of inter-laboratory differences in SARS-CoV-2 consensus genome assemblies between public health laboratories in Australia
Foster, C. S. P., Stelzer-Braid, S., Deveson, I. W., Bull, R. A., Yeang, M., Phan-Au, J., Ruiz Silva, M., van Hal, S. J., Rockett, R. J., Sintchenko, V., Kim, K. W., Rawlinson, W. D.
10.1101/2021.08.19.21262296 — Posted: 2021-08-22
Disability-adjusted life years (DALYs) due to the direct health impact of COVID-19 in India, 2020
Singh, B. B., Devleesschauwer, B., Khatkar, M. S., Lowerison, M., Singh, B., Dhand, N. K., Barkema, H. W.
10.1101/2021.08.20.21262326 — Posted: 2021-08-22
Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection
Israel, A., Shenhar, Y., Green, I., Merzon, E., Golan-Cohen, A., Schäffer, A. A., Ruppin, E., Vinker, S., Magen, E.
10.1101/2021.08.19.21262111 — Posted: 2021-08-22 Discussion: Onsite
Intention to receive a COVID-19 vaccine by HIV status among a population-based sample of women and gender diverse individuals in British Columbia, Canada
Kaida, A., Brotto, L. A., Murray, M. C. M., Cote, H. C. F., Albert, A. Y., Nicholson, V., Gormley, R., Gordon, S., Booth, A., Smith, L. W., Baaske, A., Galea, L. A. M., Sadarangani, M., Ogilvie, G. S.
10.1101/2021.08.19.21262249 — Posted: 2021-08-22

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).